New MRI technique could help surgeons prepare for brain tumor removal
NCT ID NCT06955208
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is testing whether a special type of MRI called magnetic resonance elastography (MRE) can measure how stiff a meningioma brain tumor is before surgery. Researchers will compare the MRE results with what surgeons find during the operation and with lab tests on the tumor tissue. If it works, this noninvasive scan could help surgeons plan safer and more precise tumor removals.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Magnetic Resonance Elastography (MRE)
- What this could lead to
- If successful, MRE could become a standard noninvasive tool to help surgeons predict tumor consistency and adhesion before operating, potentially improving surgical planning and safety.
- What could go wrong
- This is an early feasibility study, not a treatment trial. MRE may not accurately predict surgical findings in all cases, and results may not apply to other tumor types or hospitals.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 300 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Oct 2022
- Expected to finish
-
Oct 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 80 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * All patients undergoing meningeoma resection surgery are eligible for inclusion in the study cohort. Exclusion Criteria: * Patients with metallic implants or foreign bodies in their bodies (pacemakers, artificial metallic heart valves, metal joints, metal implants, and those who can not remove dentures, insulin pumps, or contraceptive rings) * Pregnant women in the first trimester (within three months) * Patients with severe claustrophobia or anxiety * Patients with severe fever * Patients who can not tolerate MRE * Patients with vascular malformations and aneurysms. * Patients who do not sign an informed consent
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Meningioma are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Shengjing Hospital
RECRUITINGShenyang, Liaoning, 110000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Starving brain tumors of blood before surgery
- Brain tumor or aneurysm first? study weighs the safer sequence
- Brain surgery safety: live signal monitoring may shield speech, movement, and sight
- Could blocking a Tumor's blood supply shrink brain meningiomas?
- New platform trial takes on NF2 tumors with multiple drug strategies
- Could a cancer drug shrink brain tumors and save hearing in a rare nerve disorder?